What disease is tremelimumab used to treat?

Tremelimumab/Tremelimumab is a negative regulator of the immune response and a target for cancer therapy. Blocking CTLA-4 with tremelimumab allows T cells to proliferate and attack tumor cells. TremelimumabThis cytotoxicT lymphocyte-associated antigen 4 (CTLA-4) blocking antibody is used in combination with durvalumab to treat the development of unresectable hepatocellular carcinoma (uHCC) human patients and in combination with durvalumab and platinum-based chemotherapy in adult patients with metastatic non-small cell lung cancer (NSCLC) without sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic tumor abnormalities.